ENvue Medical

NanoVibronix occupies a specialized position at the intersection of medical devices, therapeutic ultrasound, and enteral procedure guidance. Its legacy portfolio includes PainShield, a wearable ultrasound therapy device with FDA clearance, alongside UroShield and other catheter- and wound-focused products. The ENvue Medical combination adds an electromagnetic navigation platform designed to guide feeding-tube placement, differentiating the company from conventional blind insertion workflows. In enteral devices, larger established participants such as Medtronic and Cook Medical provide scale, broader distribution, and extensive hospital relationships, while NanoVibronix is competing through a more focused navigation proposition and an expanding clinical-deployment footprint. The company’s small employee band and single identified investor also indicate a materially smaller operating base than major device competitors. Its 2025 rebrand to ENvue Medical suggests management is prioritizing the enteral-navigation platform over a diversified therapeutic-device identity.

NanoVibronix’s growth trajectory shows a shift from a small therapeutic-ultrasound developer toward an enteral-navigation company supported by acquisition, hospital deployments, and repeated equity financing. The business was founded in 2003 and became publicly listed in 2017, but its most consequential inflection point occurred on Feb 14, 2025 with the announced stock-based merger involving ENvue Medical. Leadership changed on Jun 4, 2025 when Doron Besser replaced Brian Murphy as CEO, aligning executive control with the ENvue strategy. Commercial evidence strengthened during 2025: the FDA-cleared ENvue platform was shipped to a 420-bed Louisiana hospital on May 29, 2025, and two systems were agreed for implementation at an upstate New York hospital on Jun 24, 2025. The launch of Oscar as a clinician-training aid extended the platform into workflow education. Capital access also increased, with $10 million raised on May 15, 2025 and $8.89 million on Jul 18, 2025, although the disclosed rounds total less than the stated cumulative funding figure. The December 2025 name and ticker change to ENvue Medical and FEED marks the clearest signal that future growth is expected to come primarily from enteral-care products rather than legacy ultrasound therapies.